drugset / Trial / NCT05216172

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce

NCT05216172

RandomizedParallel-groupQuadruple-blindTreatment

Summary

AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce: a single site, placebo-controlled, double-blind randomised clinical trial of AZD1656 in renal transplant patients with Type 2 diabetes

Timeline

Start
2019-12-13
Primary completion
2022-09-11
Completion
2022-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule 100 mg